2013 GI ASCO GIST summary
This is a brief summary of abstracts presented at the 2013 GI ASCO meeting. Please note that abstracts have not been through a complete peer review process and are considered to be preliminary.
Understanding How GISTs Develop Enables Discovery of New Therapies
By Drs. Sebastian Bauer, West German Cancer Center, University of Essen, Germany and Jonathan Fletcher, Brigham & Women’s Hospital, Harvard University, LRG Research Team Researchers talk plainly about microGISTs, how this cancer develops and what all [...]
Understanding Drug Classes
Many new cancer drugs are entering clinical practice and clinical trials. Many GIST patients are no longer responding to Gleevec or Sutent and thus are looking for clinical trials. Understanding strategies and grouping these new drugs into classes with other similar drugs may help patients understand some of their choices.
TDM extends BLT deadline: LRG urges GISTers to take advantage
Many of us have been lucky enough to have reached a plateau of successful treatment, and in reaching this level, we may have become complacent about our care; but it is important to be proactive to ensure that we are receiving proper treatment.
PDGFRA Mutations: It’s time to consider mutational status for resistant GIST patients
January 6th, 2011 - By Jerry Call, LRG Science CoordinatorThe first ever clinical trial specifically for the PDGFRA D842V mutation has been announced by Arog pharmaceuticals. The phase II trial is scheduled to open in [...]
Analysis of an observational registry of gastrointestinal stromal tumor (GIST) patients
This poster reported the latest data from the GIST ReGISTry, an online database of GIST patient statistics maintained by a group of American and Canadian GIST specialists and supported by Novartis Pharmaceuticals.
LRG Research Team holds second in-person meeting: new tissue banking initiative born
On March 6 and 7, the LRG Research Team met for the second in-person meeting at Brigham & Women’s Hospital in Boston, Mass. The Team had previously met in Portland, Oregon at Oregon Health & [...]
KIT signaling & new approaches for GIST therapy
KIT functions in several distinct cell types. Keep reading to learn about KIT signaling and new approaches for GIST Therapy.
Hereditary GIST explained
This article explains hereditary GIST. Familial cancer syndrome is a genetic condition that causes an increased risk for specific types of cancers. Familial cancer syndromes account for only five to ten percent of all [...]
$2 million pledged for GIST research
Novartis CEO Dr. Daniel Vasella made the commitment in Boston after hearing a plea from Life Raft Executive Director Norman Scherzer. The $2 million grant is the largest single donation for GIST [...]